Bio-Works provides WorkBeads Protein A to Yumab for screening of antibody candidates now in early clinical testing against COVID-19
As a response to the COVID-19 outbreak in the spring of this year, Bio-Works offered to help by providing resins for vaccine purification research. One such project has now resulted in a neutralizing monoclonal antibody candidate against SARS-CoV-2 being produced for clinical phase 1 testing. More than 10 companies took advantage of Bio-Works’ offer of WorkBeads resins and expert advice to help speed up vaccine or treatment development against COVID-19. One of these was Yumab, a Contract Research Organization (CRO) working in a consortium together with Boehringer Ingelheim. Bio-Works